Navigation Links
Personalized medicine has finally arrived -- or has it?
Date:2/26/2014

As the price for decoding a person's DNA keeps dropping, expectations for personalized medicine based on specific genetic profiling rise. But translating an individual's genetic data into finely tailored medical treatments still faces major challenges, explains a new article in Chemical & Engineering News (C&EN), the weekly magazine of the American Chemical Society.

Rick Mullin, senior editor at C&EN, notes that advances in DNA sequencing have allowed researchers to design some therapies, particularly in the cancer realm, for patients with certain genetic traits. As the technology for reading people's genes improves and drops even further in cost, more progress is on the horizon. The U.S. Food and Drug Administration, the government body responsible for approving pharmaceuticals for commercialization, supports these efforts. With the stars seemingly aligned, some industry experts have declared that the age of personalized medicine has arrived. So why do others claim that victory is still a long way off?

The article points out that when pharmaceutical labs launched their search for new drugs based on genomics more than 15 years ago, the focus was almost exclusively on DNA sequences. But now researchers have realized that for personalized medicine to truly take hold, they need to also pay attention to individuals' health histories, their environments and how their genes actually translate into physical traits. This requires a shift in thinking, plus closer ties between the research and clinical sides, and ultimately, insurers. But perhaps the tallest barrier is cultural an attitude among some in the health care industry to simply continue business as usual.


'/>"/>

Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society
Source:Eurekalert

Page: 1

Related biology news :

1. Second-most common breast cancer subtype may benefit from personalized treatment approach
2. Can personalized tumor vaccines improve interleukin-2 treated metastatic melanoma?
3. How can we improve the efficacy of antipsychotics in the era of personalized pharmacotherapy?
4. A cost-effective way toward personalized cancer drugs
5. Oncogenic signatures mapped in TCGA a guide for the development of personalized therapy
6. "GenoVive is changing the face of personalized health by continuing research efforts with Harvard."
7. Cancer research implies future for personalized medicine, reduction in animal testing
8. Notre Dame researchers develop system that uses a big data approach to personalized healthcare
9. Frost & Sullivan Applauds geneOnyx for its DNA Testing Solution for the Personalized Cosmeceuticals Market
10. Personalized health care will revolutionize 21st century medicine, says NJIT professor
11. Personalized medicine eliminates need for drug in 2 children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... 2017   Strategic Cyber Ventures , the industry,s ... a $3.5 million investment in  Polarity , the first ... is DC based and is led by cybersecurity veterans ... Ron Gula , also a longtime cybersecurity veteran ... this series A round of funding. This new funding ...
(Date:2/22/2017)... 22, 2017 With the biometrics market ... identifies four technologies that innovative and agile startups ... share in the changing competitive landscape: multifactor authentication ...   "Companies can no longer afford ... says Dimitrios Pavlakis , Industry Analyst at ...
(Date:2/16/2017)... , Feb. 16, 2017  Genos, a community ... that it has received Laboratory Accreditation from the ... is presented to laboratories that meet stringent requirements ... scientifically rigorous processes. "Genos is committed ... laboratory practices. We,re honored to be receiving CAP ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... ... March 23, 2017 , ... Ellen Matloff, ... Connecticut Technology Council (CTC) as a 2017 Women of Innovation® finalist. Matloff will ... Innovation Awards Dinner. , The dinner recognizes women accomplished in science, technology, engineering ...
(Date:3/23/2017)... 2017 In today,s pre-market research, ... the Biotech industry: Sangamo Therapeutics Inc. (NASDAQ: SGMO), Eyegate ... SYN), and Regulus Therapeutics Inc. (NASDAQ: RGLS ... Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market Weight." Learn ... at: ...
(Date:3/22/2017)... MONICA, Calif. , March 22, 2017 /PRNewswire/ ... are proud to announce their extended partnership and ... will be headlined by the 21 st ... BIOMEDevice Boston, taking place May 3-4, 2017. ... Advanced Medical Technology Association (ADVAMED) President and CEO, ...
(Date:3/22/2017)... PALM BEACH, Florida , March 22, 2017 ... ... management for various cancer conditions are being pressured as of ... pain therapy for cancer pain management has a dramatic impact ... ramp up research and development activities for identifying new forms ...
Breaking Biology Technology: